Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination

Cancer Immunity

Volumn 5, Issue , 2005, Pages

  Chen, Qiyuan ^a   Jackson, Heather ^a   Shackleton, Mark ^a,b,c   Parente, Phillip ^a,b   Hopkins, Wendie ^a   Sturrock, Sue ^b   MacGregor, Duncan ^b   Maraskovsky, Eugene ^a   Tai, Tsin Yee ^a   Dimopoulos, Nektaria ^a   Masterman, Kelly Anne ^a   Luke, Tina ^a   Davis, Ian D ^a,b   Chen, Weisan ^a   Cebon, Jonathan ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b AUSTIN HOSPITAL   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Clinical trial; Immunological monitoring; Melanoma; Peptides; Vaccination

Indexed keywords

CD8 ANTIGEN; FLT3 LIGAND; GLUTAMINYLLEUCYLSERYLLEUCYLLEUCYLMETHIONYLTRYPTOPHYLISOLEUCYLTHREONINE[155-163]; GLUTAMYLLEUCYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE[26-35]; GLYCYLISOLEUCYLLEUCYLGLYCYLPHENYLALANYLVALYLPHENYLALANYLTHREONYLLEUCINE[58-66]; INFLUENZA MATRIX PEPTIDE; MELAN A; PEPTIDE; PEPTIDE DERIVATIVE; SERYLLEUCYLLEUCYLMETHIONYLTRYPTOPHYLISOLEUCYLTHREONYLGLUTAMINYLCYSTEINE[157-165]; SERYLLEUCYLLEUCYLMETHIONYLTRYPTOPHYLISOLEUCYLTHREONYLGLUTAMINYLCYSTEINYLPHENYLALANYLLEUCINE[157-165]; TYROSINASE INTERNAL PEPTIDE; TYROSYLMETHIONYLASPARTYLGLYCYLTHREONYLMETHIONYLSERYLGLUTAMINYLVALINE[368-376]; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; BLOOD; BLOOD ANALYSIS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOREACTIVITY; INJECTION SITE; INJECTION SITE REACTION; LYMPHOCYTIC INFILTRATION; MELANOMA; MEMORY CELL; SKIN; SYSTEMIC THERAPY; T LYMPHOCYTE ACTIVATION; VACCINATION; VALIDATION PROCESS;

EID: 18244386226     PISSN: 14249634     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ, Knuth A. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 2000; 97: 4760-5.
2. Ayyoub M, Zippelius A, Pittet MJ, Rimoldi D, Valmori D, Cerottini JC, Romero P, Lejeune F, Lienard D, Speiser DE. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res 2003; 9: 669-77.
3. Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003; 21: 2342-8.
4. Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy [review]. J Leukoc Biol 2003; 73: 3-29.
5. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000; 97: 12198-203.
6. Hladik F, Bender S, Akridge RE, Hu YX, Galloway C, Francis D, McElrath MJ. Recombinant HIV-1 glycoprotein 120 induces distinct types of delayed hypersensitivity in persons with or without pre-existing immunologic memory. J Immunol 2001; 166: 3580-8.
7. Waanders GA, Rimoldi D, Lienard D, Carrel S, Lejeune F, Dietrich PY, Cerottini JC, Romero P. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line. Clin Cancer Res 1997; 3: 685-96.
8. Cebon J, Jager E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W, Gibbs S, Chen Q, Karbach J, Jackson H, MacGregor DP, Sturrock S, Vaughan H, Maraskovsky E, Neumann A, Hoffman E, Sherman ML, Knuth A. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun 2003; 3: 7.
9. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 219-30.
10. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163: 6292-300.
11. Panelli MC, Riker A, Kammula U, Wang E, Lee KH, Rosenberg SA, Marincola FM. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol 2000; 164: 495-504.
12. Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Teates D, Neese P, Grosh WW, Petroni G, Engelhard VH, Slinglu. CL Jr. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 2001; 92: 703-11.
13. Fritsch M, Rosenberg SA, Duray PH. Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine. J Immunother 2000; 23: 557-69.
14. Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman KA, Caron D, Chen W, Maraskovsky E, Cebon J. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 2004; 4: 9.
15. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003; 9: 5091-100.
16. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 2000; 6: 1347-50.
17. Chen Q, Jackson H, Gibbs P, Davis ID, Trapani J, Cebon J. Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects. Cancer Immunol Immunother 1998; 47: 191-7.
18. Vaughan HA, Svobodova S, Macgregor D, Sturrock S, Jungbluth AA, Browning J, Davis ID, Parente P, Chen YT, Stockert E, St Clair F, Old LJ, Cebon J. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 2004; 10: 8396-404.